Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Irbesartan,Amlodipine
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Sanofi
Deal Size : Inapplicable
Deal Type : Inapplicable
Handok and Sanofi Launch “Aprovasc,” a Combination Antihypertensive Drug, in South Korea
Details : Aprovasc (Irbesartan + amlodipine) is an angiotensin II receptor blocker, small molecule drug candidate, which is indicated for the treatment of hypertension and diabetic nephropathy.
Product Name : Aprovasc
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 01, 2024
Lead Product(s) : Irbesartan,Amlodipine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Sanofi
Deal Size : Inapplicable
Deal Type : Inapplicable
AUM Biosciences enters in a Strategic Collaboration with Handok and CMG Pharm to develop CHC2014
Details : CHC2014 is completing a Phase I in Korea and has shown promising data to justify advancement to a tumor agnostic registrational program. CHC2014 has shown superior in-vivo anti-tumor activity compared to available treatment options.
Product Name : CHC2014
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
November 05, 2021